Operating costs

12 Months Ended

Dec. 31, 2017

Expenses by nature [abstract]

Operating costs

6.      Operating costs

Operating result has been calculated after charging (-) / crediting:

RESEARCH AND DEVELOPMENT EXPENDITURE

The following table summarizes research and development expenditure for the years ended December 31, 2017, 2016 and 2015.

	Year ended December 31,
	2017		2016		2015
		(Euro, in thousands)
Personnel costs	€	(59,950)	€	(42,315)	€	(35,875)
Subcontracting		(123,054)		(65,649)		(65,883)
Disposables and lab fees and premises costs		(22,277)		(20,414)		(18,696)
Other operating expenses		(13,221)		(11,196)		(9,260)
Total R&D expenditure	€	(218,502)	€	(139,573)	€	(129,714)

The table below summarizes our research and development expenditure for the years ended December 31, 2017, 2016 and 2015, broken down by research and development expenses under alliance and own funded research and development expenses. All filgotinib costs (both costs incurred in the period under alliance (with AbbVie) and costs incurred after AbbVie’s opt-out decision in September 2015) are presented as “R&D under alliance” or as “partnered” in the tables in this section for the year ended December 31, 2015, as a new alliance was signed in December 2015 with Gilead for this program.

	Year ended December 31,
	2017		2016		2015
		(Euro, in thousands)
R&D under alliance	€	(122,663)	€	(71,980)	€	(80,832)
Galapagos funded R&D		(95,839)		(67,593)		(48,882)
Total R&D expenditure	€	(218,502)	€	(139,573)	€	(129,714)

All research and development expenditures are tracked against detailed budgets and allocated by individual project. The table below summarizes our research and development expenditure for the years ended December 31, 2017, 2016 and 2015, broken down by program.

	Year ended December 31,
	2017		2016		2015
	(Euro, in thousands)
Filgotinib program (partnered)	€	(53,212)	€	(22,376)	€	(35,404)
CF program (partnered)		(46,192)		(31,203)		(25,634)
IPF program on GLPG1690 (proprietary)		(16,190)		(7,129)		(4,612)
OA program on GLPG1972 (partnered)		(7,317)		(6,538)		(5,832)
AtD program on MOR106 (partnered)		(8,404)		(3,491)		(4,651)
Other		(87,187)		(68,836)		(53,582)
Total R&D expenditure	€	(218,502)	€	(139,573)	€	(129,714)

GENERAL AND ADMINISTRATIVE EXPENSES

The following table summarizes the general and administrative expenses for the years ended December 31, 2017, 2016 and 2015.

	Year ended December 31,
	2017		2016		2015
		(Euro, in thousands)
Personnel costs and directors fees	€	(17,756)	€	(15,160)	€	(12,739)
Other operating expenses		(6,659)		(6,584)		(6,388)
Total general and administrative expenses	€	(24,415)	€	(21,744)	€	(19,127)

SALES AND MARKETING EXPENSES

The following table summarizes the sales and marketing expenses for the years ended December 31, 2017, 2016 and 2015.

	Year ended December 31,
	2017		2016		2015
		(Euro, in thousands)
Personnel costs	€	(2,156)	€	(1,167)	€	(785)
Other operating expenses		(646)		(618)		(397)
Total sales and marketing expenses	€	(2,803)	€	(1,785)	€	(1,182)